See more : Tobii Dynavox AB (publ) (TDVOX.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Pear Therapeutics, Inc. (PEAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pear Therapeutics, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- GuestLogix Inc. (GUESF) Income Statement Analysis – Financial Results
- Applied Graphite Technologies Corporation (AGT.V) Income Statement Analysis – Financial Results
- Tharisa plc (TIHRF) Income Statement Analysis – Financial Results
- Cohen Circle Acquisition Corp. I (CCIRU) Income Statement Analysis – Financial Results
- Jinzhou Jixiang Molybdenum Co., Ltd. (603399.SS) Income Statement Analysis – Financial Results
Pear Therapeutics, Inc. (PEAR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://peartherapeutics.com
About Pear Therapeutics, Inc.
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.69M | 4.21M | 9.38M | 32.56M |
| Cost of Revenue | 8.18M | 5.23M | 1.72M | 998.00K |
| Gross Profit | 4.51M | -1.03M | 7.67M | 31.56M |
| Gross Profit Ratio | 35.54% | -24.36% | 81.69% | 96.94% |
| Research & Development | 48.31M | 37.04M | 28.08M | 35.70M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.55M | 67.62M | 56.23M | 27.47M |
| Other Expenses | 0.00 | -2.05M | -16.82M | 544.00K |
| Operating Expenses | 127.86M | 104.66M | 84.31M | 63.17M |
| Cost & Expenses | 136.04M | 109.89M | 86.03M | 64.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.42M |
| Interest Expense | 3.89M | 0.00 | 2.56M | 0.00 |
| Depreciation & Amortization | -46.05M | -46.74M | 1.43M | -20.10M |
| EBITDA | -169.40M | -152.43M | -75.22M | -51.70M |
| EBITDA Ratio | -1,334.48% | -3,622.27% | -801.52% | -158.79% |
| Operating Income | -123.35M | -105.69M | -76.64M | -31.60M |
| Operating Income Ratio | -971.72% | -2,511.53% | -816.75% | -97.05% |
| Total Other Income/Expenses | 47.86M | 40.54M | -12.17M | 22.27M |
| Income Before Tax | -75.49M | -65.14M | -97.02M | -9.33M |
| Income Before Tax Ratio | -594.70% | -1,548.05% | -1,033.92% | -28.67% |
| Income Tax Expense | -51.75M | -44.85M | 3.56M | -21.73M |
| Net Income | -23.74M | -20.29M | -100.58M | 12.39M |
| Net Income Ratio | -187.02% | -482.27% | -1,071.86% | 38.05% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 138.71M | 113.33M | 137.80M | 137.80M |
| Weighted Avg Shares Out (Dil) | 138.71M | 113.33M | 137.80M | 137.80M |
Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?
Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Pear Has Captive Markets With reSET, Guides $30 Million In 2023
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript
Pear Therapeutics Reports Third Quarter 2022 Results
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Pear Therapeutics (PEAR)
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
Source: https://incomestatements.info
Category: Stock Reports